

## Research Article

# Stress Management in Women with Hashimoto's thyroiditis: A Randomized Controlled Trial

Zoe S Markomanolaki<sup>1</sup>, Xanthi Tigani<sup>1</sup>, Thomas Siamatras<sup>2</sup>, Flora Bacopoulou<sup>3</sup>, Athanasios Tsartsalis<sup>2</sup>, Artemios Artemiadis<sup>1</sup>, Vasileios Megalooikonomou<sup>4</sup>, Dimitrios Vlachakis<sup>5,6</sup>, George P Chrousos<sup>1,3\*</sup> and Christina Darviri<sup>1\*</sup>

<sup>1</sup> Postgraduate Course of Stress Management and Health Promotion, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece

<sup>2</sup> Naval Hospital of Athens, Greece

<sup>3</sup> Center for Adolescent Medicine and UNESCO Chair on Adolescent Health Care, First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, Athens 11527, Greece

<sup>4</sup> Computer Engineering and Informatics Department, School of Engineering, University of Patras, Patras 26500, Greece

<sup>5</sup> Laboratory of Genetics, Department of Biotechnology, School of Food, Biotechnology and Development, Agricultural University of Athens, 75 Iera Odos, 11855, Athens, Greece

<sup>6</sup> Lab of Molecular Endocrinology, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

\*Equal contribution

Received on January 13, 2019; Accepted on January 27, 2019; Published on July 28, 2019

Correspondence should be addressed to Flora Bacopoulou; Tel: +306973208208 ; Fax: +30 2132013237, Email: bacopouf@hotmail.com

## Abstract

**Aim:** Stress has been implicated in the pathogenesis of Hashimoto's thyroiditis (HT), nevertheless evidence is scarce regarding the effect of stress management on individuals suffering from HT. The purpose of this study was to evaluate the impact of an 8-week stress management intervention on the anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies as well as thyroid-stimulating hormone (TSH) levels of women with HT. Secondary endpoints included the effect on the patients' lifestyle, body mass index (BMI), depression, anxiety and stress. **Methods:** This was a two-arm parallel group (stress management intervention vs. standard care groups) randomized con-

trolled study. Adult women with Hashimoto's thyroiditis, completed questionnaires on stress, anxiety, depression and lifestyle, at the beginning of the programme and 8 weeks later. Laboratory thyroid function tests (anti-TPO, anti-TG antibodies and TSH) were also measured at baseline and at the end of the study. **Results:** A total of 60 women with HT, aged 25-76 years, participated in the study (30 patients in each group). After eight weeks, patients in the intervention group demonstrated statistically significant beneficial decrements in the rate change of anti-TG titers and the levels of stress, depression and anxiety as well as better lifestyle scores, compared to the control group.

## Introduction

Autoimmune thyroiditis affects a large percentage of the population worldwide and is attributed to a combination of genetic and environmental factors (Wasserman *et al.* 2009). Hashimoto's thyroiditis (HT), the most common type of autoimmune thyroiditis, is characterized by the detection of antithyroid antibodies i.e. anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies with or without symptoms of hypothyroidism (e.g. weight gain, fatigue, cold intolerance, hair loss, dry skin, constipation etc.) (Hadj-Kacem *et al.* 2009).

Apart from physical health, patients may experience the ramifications of HT in their mental health and quality of life in general (Jonklaas & Burman, 2013) as they often report symptoms of chronic fatigue, irritability, memory or other cognitive problems (Ott *et al.* 2011). Several psychiatric co-morbidities have been reported (e.g. depression, anxiety, panic disorder etc.), although depression constitutes the capstone of these disorders especially in overt hypothyroidism (Kung 1995, Matsubayashi *et al.* 1996, Radosavljevic *et al.* 1996). The end result of these multiple health problems is that patients are subject to great stress.

Although stress has not been recognized as a

**Table 1.** Timeline and content of the program sessions

Sessions timeline	Session content
1 <sup>st</sup> week	Lifestyle and routine changes to healthier direction
2 <sup>nd</sup> week	Diaphragmatic breathing
3 <sup>d</sup> week	Progressive relaxation technique
4 <sup>th</sup> week	Cognitive reconstruction
5 <sup>th</sup> week	Diet adjustments
6 <sup>th</sup> week	Guided imagery
7 <sup>th</sup> , 8 <sup>th</sup> week	Conversation and encouraging the adoption of the techniques

risk factor for HT, it is well-established that it affects endocrine and immune mechanisms implicated also in HT (Chrousos & Elenkov 2006, Mikoš 2014, Tsatsoulis 2006). For instance, hyperactivity of the hypothalamic-pituitary- adrenal axis of stress results in increased levels of cortisol in the bloodstream causing downregulation of the thyroid hormones and hypothyroidism (Tsigos & Chrousos 2002). Also, acute stress has immuno-enhancing properties favoring inflammation (Dhabhar 2014, Tsigos & Chrousos 2002) which in the context of autoimmunity could result in clinical relapse. On the other hand, chronic stress is associated with many perturbations of the immune system, mainly with Th1 to Th2 shift, leading to enhanced humoral responses (Elenkov & Chrousos 1999, Wilder 2002).

So far, there is scarce evidence on the role of stress management in HT. Patients with HT might benefit from interventions focusing on ameliorating anxiety, stress, depression and improving healthy lifestyle. The biopsychosocial intervention NET (Neuro-Emotional Technique) showed no benefits for thyroid function tests and physical, mental and general health (Brown *et al.* 2015). On the other hand, the intervention held by Moncayo and Moncayo (2014), which included magnesium supplementation and relaxation treatment, was notably beneficial leading to improvement of the psychological stress and the thyroid-related symptoms in 90% of patients with thyroiditis.

The primary aim of this two-arm randomized controlled study was to examine the impact of a stress management program on the thyroid antibodies and thyroid-stimulating hormone (TSH) levels of women with HT. Secondary endpoints included the effect on body mass index (BMI), lifestyle, depression, anxiety and stress.

## Materials and Methods

This two-arm, parallel group, non-blind, randomized controlled study was conducted at the Naval Hospital of Athens in Greece, from November 2015 to July 2016, after receiving approval by the Ethics and Education Committee of the hospital. Eligible participants were adult women ( $\geq 18$  years of age) with Hashimoto's thyroiditis, residents of Athens and literate in Greek. Patients were excluded if they suffered a mental illness, received any medication or participated in any other stress management program.


The participants who met the inclusion criteria were randomized in two groups on the basis of random numbers generated by web-based random number generator to cosmic radiation (random.org). The participants of each group were informed about the purpose of the program. After obtaining written informed consent to participate in the study, they completed questionnaires for baseline measurements.

The intervention group participated in an 8-week stress management program which included stress management and lifestyle counseling in 8 weekly sessions. Controls received standard care by their physicians. The timeline and content of the stress management program are presented in Table 1.

## Measurements

### Socio-demographic and Anthropometric Characteristics

Participants' socio-demographic characteristics i.e. age, education, marital and smoking status as well as BMI (i.e. their weight in kilograms divided by the square of their height in meters) were recorded upon

**Figure 1.** Diagram depicting the study flow chart.

**Table 2.** Baseline socio-demographic characteristics of the study sample (N=60).

Characteristic	Intervention (N=30)	Control (N=30)	P value
Age, mean $\pm$ SD <sup>1</sup>	45.7 $\pm$ 11.6	46.8 $\pm$ 11.7	0.72
Married, N (%) <sup>2</sup>	16 (53.3)	22 (73.3)	0.18
Education <sup>2</sup>			0.79
Primary, N (%)	2 (6.7)	3 (10)	
Secondary, N (%)	9 (30)	7 (23.3)	
Tertiary, N (%)	19 (63.3)	20 (66.7)	
Smoking, N (%) <sup>2</sup>	6 (20)	8 (26.7)	0.76

entry and at the end of the study.

#### Levels of anti-TPO, anti-TG and TSH

Thyroid function tests were evaluated at baseline and after 8 weeks. Levels of thyroid autoantibodies (anti-TPO, anti-TG) were measured with the classic method of immunofluorescence and TSH was measured with the chemiluminescent third-generation method, as described elsewhere (Spencer 2013).

#### Health Lifestyle and Personal Control Questionnaire (HLPCQ)

The healthy lifestyle and personal control questionnaire (HLPCQ), is a psychometric tool consisting of 26-items, designed for and weighted in the Greek population (Darviri *et al.* 2014). Respondents are asked to indicate the frequency of some habits in their everyday life on a Likert-type scale (1 = never or rarely, 2 = sometimes, 3 = often 4 = always). Twelve questions refer to nutrition, 8 refer to daily time management, 2 refer to organized physical activity and 4 are about social support practices and positive thinking (eg, "cleaning" of the mind during sleep). Higher scores indicate healthier lifestyle. Separate scores can be obtained on the following subscales: healthy dietary choices, unhealthy dietary avoidance, daily routine, organized physical activity, social support and mental control.

#### Depression Anxiety Stress Scale-21 (DASS-21)

DASS-21 is a questionnaire that has three subscales: depression, anxiety and stress (Lovibond & Lovibond 1995). Each subscale includes 7 items to which the respondent is invited to answer via a 5-point Likert-type scale. Higher scores indicate higher stress, anxiety or depression. This scale has been validated in the Greek population (Lyraeos *et al.* 2009).

#### Statistical analysis

Baseline socio-demographic and outcome data are presented as means, standard deviations (SD), or frequencies within groups. Between group comparisons for baseline data were performed using Pearson's chi-square and Student's t tests for categorical and interval characteristics, respectively. There were no missing data in the dataset. Longitudinal changes in outcome measures from baseline to 8 weeks (or rate of outcome change) were analyzed using linear mixed-effects models with interaction terms for study group and time points. Random intercepts  $b_0$  were used for the random effect of each participant in the model using variance components structure. The models' formula was the following:

$$Y_{ti} = b_0 + b_1(\text{TIME}_{ti}) + b_2(\text{GROUP}_i) + b_3(\text{GROUP}_i) \times (\text{TIME}_{ti}) + b'_0 + e_{ti}$$

where  $Y_{ti}$  is the outcome,  $b_0$  is the intercept,  $b_1$ ,  $b_2$ ,  $b_3$ , are the fixed coefficients,  $b'_0$  is the random coefficient for intercept,  $\text{TIME}_{ti}$  is the time point (t) for each individual (i),  $\text{GROUP}_i$  is the intervention condition and  $e_{ti}$  is the time specific residual of the model. The  $H_0$  null hypothesis of interest was  $b_3=0$ . By coding control group and baseline time as zeros (intervention and follow-up time as one)  $b_3$  represents the difference of the average rate of outcome of the intervention group relative to the control group.

The Reliable Change Index (RCI) was calculated for each outcome questionnaire (Jacobson & Truax, 1991). An absolute RCI above 1.96 denotes significant difference after taking into account scores, score variance and questionnaire's reliability. RCI was calculated according to the formula:  $\text{RCI} = (X_2 - X_1) \div \sqrt{(\text{SEM}_1^2 + \text{SEM}_2^2)}$ , where  $X_2$  and  $X_1$  are the final and baseline outcome values and SEM is the standard

**Table 3.** Baseline outcome characteristics of the study groups (N=60)<sup>1</sup>.

Characteristic	Intervention (N=30) Mean $\pm$ SD	Control (N=30) Mean $\pm$ SD	P value
anti-TPO (IU/ml)	506.2 $\pm$ 1248.2	352.0 $\pm$ 525.6	0.54
anti-TG (IU/ml)	451.1 $\pm$ 808.4	385.1 $\pm$ 759.5	0.75
TSH (IU/ml)	2.2 $\pm$ 1.5	1.9 $\pm$ 1.4	0.58
BMI (Kg/m <sup>2</sup> )	24.4 $\pm$ 4.7	25.8 $\pm$ 5.4	0.30
HLPCQ	66.2 $\pm$ 13.1	64.6 $\pm$ 15.2	0.65
Stress	7.5 $\pm$ 4.2	6.9 $\pm$ 4.7	0.65
Depression	4.4 $\pm$ 4.2	4.8 $\pm$ 5.2	0.74
Anxiety	4.5 $\pm$ 4.2	3.0 $\pm$ 2.9	0.13

BMI: Body Mass Index, anti-TPO: Thyroid Peroxidase Antibody, anti-TG: Thyroglobulin Antibody, TSH: Thyroid Stimulating Hormone, HLPCQ: Healthy Lifestyle and Personal Control Questionnaire, <sup>1</sup>Student's t-test

**Table 4.** Results of the linear mixed-effects models for the rates of outcome change.

Outcomes	b for group × time interaction <sup>1</sup> (SE)	P value
anti-TPO (IU/ml)	-307.4 (211.6)	0.15
anti-TG (IU/ml)	-112.4 (43.6)	0.01*
TSH (IU/ml)	-0.6 (0.3)	0.07
BMI (Kg/m <sup>2</sup> )	-0.48 (0.2)	0.06
HLPCQ	20.2 (2.8)	<0.001*
Stress	-4.0 (0.8)	<0.001*
Depression	-1.9 (0.7)	0.01*
Anxiety	-1.9 (0.7)	0.01*

BMI: Body Mass Index, anti-TPO: Thyroid Peroxidase Antibody, anti-TG: Thyroglobulin Antibody, TSH: Thyroid Stimulating Hormone, HLPCQ: Healthy Lifestyle and Personal Control Questionnaire, SE: Standard Error, b: b coefficient of the linear mixed-effect model for the Rates of Outcome Change.

<sup>1</sup>Reference categories: control group and baseline (both coded as zeros)

\* $P < 0.05$

error measurement calculated by the formula: standard deviation (in time1 or 2) \*  $\sqrt{1 - \text{Cronbach's alpha in time 1 or 2}}$ . The Number Needed to Treat (NNT) for each questionnaire was calculated (i.e. the number of individuals that we need to treat in order to attain significant improvement in 1 subject). All analyses were performed using SPSS 22.0v for Windows (Chicago IL).

## Results

Figure 1 shows the study flowchart. Overall, 97 patients were approached and of these, 30 were excluded (19 did not meet the inclusion criteria, 11 refused to participate). Of the 67 participants, 34 were randomized to the intervention group, with four drop outs during the intervention (one patient left Athens and three failed monitoring due to increased family

responsibilities). From the control group, three patients discontinued due to major life events. Finally, a total of 60 women were analyzed (30 patients in each group).

Table 2 presents the socio-demographic characteristics of the study sample. Most women were of middle age, married, of tertiary education and non-smokers. No statistically significant group comparisons were noted. Table 3 presents baseline measurements for all the outcomes' scores. There were no statistically significant differences between the study groups at baseline.

Table 4 presents the results of the mixed-effects models for the rates of outcomes' changes across time. Significant interaction between group and time (b3 in the model equation) was recorded for anti-TG, indicating a favorable effect of the intervention on these antibody titers. Patients in the intervention group demonstrated statistically significant beneficial decrements in the rate change of stress, depression and anxiety. The HLPCQ score was also significantly increased in the intervention group compared to the control group. Although, there was a decreasing trend of anti-TPO and TSH in the intervention group compared to controls, the differences were not statistically significant.

According to Table 5, 23.3-50.0% of patients had significant score changes according to the RCI index used for the questionnaires. Based on NNT the strongest effect was noted for lifestyle as assessed by the HLPCQ.

## Discussion

In this randomized controlled study, an 8-week stress management program was implemented in women with HT, to assess its impact on their thyroid function tests, mental health and lifestyle. Overall, the study showed that patients in the intervention group decreased the anti-TG titers, their stress, anxiety and depression levels and adopted a healthier lifestyle. The latter effect was found to be the strongest among the study measurements based on questionnaires. So far, there are no similar studies which corroborate or contradict these results. The NET study (which

**Table 5.** Number of individuals with beneficial significant change scores according to the Reliable Change Index and the corresponding Number Needed to Treat values (NNT).

Characteristic (Cronbachs' alpha before, after)	Intervention N, (%)	Control N, (%)	NNT
HLPCQ (0.90, 0.94)	15 (50)	0 (0)	2
Stress (0.84, 0.83)	8 (26.7)	0 (0)	12.5
Depression (0.88, 0.89)	7 (23.3)	3 (10)	25
Anxiety (0.81, 0.79)	7 (23.3)	0 (0)	14.3

HLPCQ: Healthy Lifestyle and Personal Control Questionnaire

resulted in no clinical benefit for the patients) used a different approach to stress management in relation to our techniques (Brown *et al.* 2015). The WOMED approach for Hashimoto disease by Moncayo and Moncayo (2014), showed treatment success in 90% of the cases, using techniques that involved acupuncture for stress relief only to patients with high stress levels and magnesium supplementation to patients with low serum magnesium and residual symptoms of hypothyroidism. Therefore, the results of our study are not comparable to any of the studies' findings mentioned above.

A limitation of the study was the lack of objective ascertainment of compliance to the stress management program. Patients were asked to keep a diary of the techniques they performed at home. Although their diary records showed in general perfect compliance, this is still a self-report assessment. Secondly, HT-related symptoms, which are more indicative of the disease severity, were not evaluated, although most patients were in clinical remission. Finally, the study did not seek for long-term data, after the end of the 8-week period.

To our knowledge, this is the first study showing a reduction of anti-TG titers in women with HT undergoing a stress management intervention. Although, the observed benefits in lifestyle and psychological health (i.e. stress, depression, anxiety) could account for this finding, more targeted research on the subject is needed to draw such a conclusion. So far, there is no definite epidemiological evidence linking stress to HT. Presumably, stress reduction could lead to decreased humoral immune responses which are responsible for antibody production (Dhabhar 2014). With regards to pathophysiology, although the connection of stress with Grave's disease has been adequately evidenced, this is not the case with HT (Damian *et al.* 2016). The pathogenesis of HT includes both cell- (Th1 and Th17) and humoral-mediated (anti-TPO, anti-TG) immune mechanisms, thus the role of stress should be complex. However, there is still enough room for speculation; acute stress might exacerbate HT, while chronic stress favoring a Th1 to Th2 shift might be related to increased blood levels of the anti-TPO and anti-TG antibodies (Dhabhar 2014). As such, it is reasonable to expect from effective stress management intervention to lower the levels of these antibodies in the bloodstream.

In conclusion, short-term stress management had beneficial effects on the anti-TG titers, the lifestyle and the psychological status of women with HT. Given the absence of similar studies, further research is warranted. The role of stress management in the everyday clinical practice of physicians treating patients with HT is still questionable. However, the remote possibility of causing any harm, renders stress management a safe personalized choice for physicians and patients.

## Acknowledgments

We would like to thank the Endocrinologists Nikolaos Mazarakis, Ioannis G. Komminos and the Nephrologist Ioannis Tsouras, for their assistance, well as the patients for their commitment to the study.

## Conflict of Interest

Authors declare no conflicts of interest.

## Authors' contributions

ZM designed the study, recruited patients, collected, analyzed the data and wrote the initial draft. TS recruited patients and supervised laboratory analyses. AT supervised laboratory analyses. FB and AA supervised data analysis and critically revised the manuscript. XT, MV, DV, GPC and CD supervised the project. All authors read and approved the final manuscript.

## References

- Brown BT, Graham PL, Bonello R & Pollard H 2015 Biopsychosocial approach to primary hypothyroidism: treatment and harms data from a randomized controlled trial. *Chiropr Man Therap* **23** 24
- Chrousos GP & Elenkov IJ 2006 Interactions of the endocrine and immune systems. In: DeGroot LJ, Jameson JL (eds.), *Endocrinology*, Saunders Elsevier, Philadelphia, PA, Vol. 1. pp. 799-818
- Damian L, Ghiciuc CM, Dima-Cozma LC, Ungureanu MC, Cozma S, Patacchioli FR & Lupusoru CE 2016 No definitive evidence for a connection between autoimmune thyroid diseases and stress in women. *Neuro Endocrinol Lett* **37** 155-162
- Darviri C, Alexopoulos EC, Artemiadis AK, Tigani X, Kraniotou C, Darviri P & Chrousos GP 2014 The Healthy Lifestyle and Personal Control Questionnaire (HLPCQ): a novel tool for assessing self-empowerment through a constellation of daily activities. *BMC Public Health* **14** 995
- Dhabhar FS 2014 Effects of stress on immune function: the good, the bad, and the beautiful. *Immunol Res* **58** 193-210
- Elenkov IJ & Chrousos GP 1999 Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease. *Trends Endocrinol Metab* **10** 359-368
- Hadj-Kacem H, Rebuffat S, Mnif-Féki M, Belguith-Maalej S, Ayadi H & Péraldi-Roux S 2009 Autoimmune thyroid diseases: genetic susceptibility of thyroid-specific genes and thyroid autoantigens contributions. *Int J Immunogenet* **36** 85-96
- Jacobson NS & Truax P 1991 Clinical significance: a statistical approach to defining meaningful change in psychotherapy-research. *J Consult Clin Psychol* **59** 12-

19.

Jonklaas J, Burman KD, Bianco AC & American Thyroid Association Spring 2013 Program Committee 2013 Treatment of hypothyroidism: possibilities on the horizon. *Thyroid* **23** ix-xi.

Kung AW 1995 Life events, daily stresses and coping in patients with Graves' disease. *Clin Endocrinol* **42** 303-308

Lovibond SH & Lovibond PF 1995 Manual for the Depression Anxiety Stress Scales, 2nd Ed., Sydney: Psychology Foundation, ISBN 7334-1423-0

Lyrakos G & Arvaniti C 2009 Greek translation of the DASS. Retrieved from <http://www2.psy.unsw.edu.au/dass/Greek/Greek.htm> on June 30 2019

Matsubayashi S, Tamai H, Matsumoto Y, Tamagawa K, Mukuta T, Morita T & Kubo C 1996 Graves' disease after the onset of panic disorder. *Psychother Psychosom* **65** 277-280

Mikoś H, Mikoś M, Obara-Moszyńska M & Niedziela M 2014 The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). *Endokrynol Pol* **65** 150-155

Moncayo R & Moncayo H 2014 The WOMED model of benign thyroid disease: acquired magnesium deficiency due to physical and psychological stressors relates to dysfunction of oxidative phosphorylation. *BBA Clin* **3** 44-64

Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC & Hermann M 2011 Hashimoto's thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. *Thyroid* **21** 161-167

Radosavljevic VR, Jankovic SM & Marinkovic JM 1996 Stressful life events in the pathogenesis of Graves' disease. *Eur J Endocrinol* **134** 699-701

Spencer CA 2013 Assay of Thyroid Hormones and Related Substances. [www.endotext.org](http://www.endotext.org). Retrieved 5 November 2014

Tsatsoulis A 2006 The role of stress in the clinical expression of thyroid autoimmunity. *Ann NY Acad Sci* **1088** 382-395

Tsigos C & Chrousos GP 2002 Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. *J Psychosom Res* **53** 865-871

Wasserman EE, Nelson K, Rose NR, Rhode C, Pillion JP, Seaberg E, Talor MV, Burek L, Eaton W, Duggan A & Yolken RH 2009 Infection and thyroid autoimmunity: A seroepidemiologic study of TPOAb. *Autoimmunity* **42** 439-446

Wilder RL 2002 Neuroimmunoendocrinology of the rheumatic diseases: past, present, and future. *Ann N Y Acad Sci* **966** 13-19